Premium Aficamten API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Aficamten (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Selective Cardiac Myosin Inhibitor

Indications: Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Aficamten distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Aficamten is a next-generation, orally bioavailable small-molecule Active Pharmaceutical Ingredient (API). In cardiovascular pharmacology, it represents a highly specialized class of therapeutics known as selective cardiac myosin inhibitors. For pharmaceutical manufacturers focused on expanding their cardiology portfolios, this API provides a targeted approach to treating diseases that directly affect the heart muscle (myocardium).

At the molecular level, Aficamten directly targets the core defect of hypertrophic cardiomyopathy (HCM). The pathophysiology of HCM is characterized by severe myocardial hypercontractility, driven by an excessive number of active actin-myosin cross-bridges during the cardiac cycle, which leads to left ventricular outflow tract obstruction (LVOTO).

By selectively binding to a distinct allosteric site on the cardiac beta-myosin motor protein, Aficamten stabilizes the myosin in a low-actin-affinity, energy-conserving "super-relaxed" state. This action prevents the myosin heads from entering a force-producing state.

As a result, the API predictably reduces excessive sarcomere contractility and decreases myocardial adenosine triphosphate (ATP) consumption without altering intracellular calcium handling or interfering with systemic beta-adrenergic signaling. For formulation scientists, this active ingredient provides the foundation for developing oral cardiovascular therapies that address obstruction and improve diastolic function. In standard commercial manufacturing, this API is typically formulated into low-dose immediate-release oral solid tablets or capsules.

Sourcing Aficamten in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced cardiovascular formulations requires a highly resilient and traceable raw material pipeline. Procuring specialized cardiology APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing Aficamten Pakistan through Morgan’s localized distribution network actively mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you require a standard pilot batch or are scaling up a high-volume Aficamten api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages or raw material shortages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during dry blending and tablet compression processes.

Technical Specifications for QA & R&D

The Aficamten API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-pyrazole-4-carboxamide
• CAS Number: 2364554-48-1
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C18H19N5O2
• Molecular Weight: 337.38 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents (such as DMSO and methanol) and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

Aficamten is a highly potent, targeted cardiovascular compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature or refrigerated between 2-8°C, strictly protected from excessive heat and ambient humidity) to prevent degradation and maintain structural integrity.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or powered air-purifying respirators (PAPR), chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure containment isolators to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.